首页 › 基金 › Menlo Ventures Management, L.P. › SYRE
Menlo Ventures Management, L.P. 对 SYRE 的持仓历史
SCRIBE THERAPEUTICS INC · 医疗保健
Menlo Ventures Management, L.P. 在 Q3 2026 的 13F 申报中披露持有 SYRE(SCRIBE THERAPEUTICS INC)97,690 股,市值约 US$1.8M,约占其申报组合的 0.75%,在其申报持仓中市值排名第 3 位。 Menlo Ventures Management, L.P. 于 Q3 2026 首次申报该持仓。
最后更新: 2026-11-07 · 来源: SEC EDGAR Form 13F-HR
Menlo Ventures Management, L.P. 对 SYRE 的持仓演变
Menlo Ventures Management, L.P. 于 Q3 2026 首次披露 SYRE 持仓:97,690 股(约 US$1.8M)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2026 | 97.69K | $1.80M | 新进 |
关于 SYRE 与 13F 数据
SYRE(SCRIBE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 71 只申报持有 SYRE,申报仓位最大的包括:PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 SYRE 的基金
- PERCEPTIVE ADVISORS LLC 4.32M 股 · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M 股 · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M 股 · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M 股 · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M 股 · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M 股 · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M 股 · $167.99M · Q2 2026
- Remedium Capital Partners, LLC 1.46M 股 · $129.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M 股 · $113.56M · Q2 2026
- Siren, L.L.C. 968.60K 股 · $85.99M · Q2 2026
- BRAIDWELL LP 879.47K 股 · $78.08M · Q2 2026
- Commodore Capital LP 846.79K 股 · $75.18M · Q2 2026
更多关于 Menlo Ventures Management, L.P.
常见问题
How long has Menlo Ventures Management, L.P. held SYRE?
Menlo Ventures Management, L.P. has disclosed SYRE holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Menlo Ventures Management, L.P.'s current position in SYRE?
As of Q3 2026, Menlo Ventures Management, L.P. holds 97.69K shares of SYRE (SCRIBE THERAPEUTICS INC), valued at $1.80M, representing 0.75% of its reported portfolio and ranking #3.
Has Menlo Ventures Management, L.P. been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Menlo Ventures Management, L.P. newly opened its position in SYRE.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.